EU Approves Higher-Dose Wegovy for Enhanced Weight Loss

Feb 19, 2026

69 min

Feb 19, 2026 07:32

New higher-dose Wegovy approved in Europe after study shows 21% weight loss

## New Treatment Option for Obesity

The European Union has approved a higher-dose version of the weight-loss drug Wegovy, offering a new option for patients who need more significant weight reduction. This decision follows a positive recommendation from the European Medicines Agency and applies to all 27 EU member states.

## Clinical Trial Success

The approval was based on clinical trials involving nearly 2,000 participants. These trials showed that the higher 7.2 mg dose led to an average weight loss of about 21% over 18 months. Approximately one-third of participants lost more than 25% of their body weight, a significant achievement in obesity treatment.

## Dosage and Administration

The new dosage is intended for adults who have completed treatment with the existing 2.4 mg dose but require further weight loss. The 7.2 mg dose can be administered through three injections of the current 2.4 mg formulation. A single-dose pen for this higher strength is under review and may become available later this year.

## Side Effects and Market Impact

Common side effects reported include nausea, diarrhea, and vomiting, which were generally mild and temporary. The approval comes amid increasing demand for weight-management therapies due to rising obesity rates and associated health risks. Wegovy is now available in the EU in doses ranging from 0.25 mg to 7.2 mg, making it one of the most flexible options in the market.

Read the full story at the source

What you need to know to get Emirates ID?

Leave your details and get a guide as a gift to avoid mistakes

Article contents